Academic Journals Database
Disseminating quality controlled scientific knowledge

FORMULATION, DEVELOPMENT AND EVALUATION OF EXTENDED RELEASE TABLET OF PENTOXIFYLLINE

ADD TO MY LIST
 
Author(s): Mahesh W. Thube

Journal: International Journal of Pharmaceutical Research and Development
ISSN 0974-9446

Volume: 2;
Issue: 4;
Start page: 9;
Date: 2010;
Original page

Keywords: HPMC | Matrix Tablet | Extended Release | Pentoxifylline | Experimental Design

ABSTRACT
The work aims to formulate pentoxifylline extended release matrix tablet of hydrophilic polymer HPMC K15M and hydrophobic polymer MCC 101 combination using 32 factorial designs. Pentoxifylline is the hemorrheologic agent, lowering blood viscosity, and improving erythrocyte flexibility. It is having half life 0.4 - 0.8 hours (1-1.6 hours for active metabolite) with the usual oral dose is 400 mg three times daily.Nine formulations were prepared and dissolution studies were performed. The dissolution data obtained were fitted to the PCP disso version 3 software. Linear regression analysis and model fitting depicted that the formulations followed Peppas-Korsmeyer Equation suggesting “Anomalous Transport” release mechanism. The two formulation variables were found to be significant for the release properties (P < 0.05). The quadratic mathematical model developed could be used to further predict formulations with desirable release. The similarity factor f2 was found to be 55.75 for the developed formulation indicating the release was similar to that of the marketed formulation (Trental®). Thus, a combination of HPMC K15M and MCC 101 extends the release for a period of 24 hrs.
Save time & money - Smart Internet Solutions      Why do you need a reservation system?